TISIDB

Summary
Symbol	MYH4
Name	myosin, heavy chain 4, skeletal muscle
Aliases	MYH2B; MyHC-2B; MyHC-IIb; myosin, heavy polypeptide 4, skeletal muscle; myosin heavy chain 2b; myosin heavy ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm, myofibril. Note=Thick filaments of the myofibrils.
Domain	PF00063 Myosin head (motor domain) PF02736 Myosin N-terminal SH3-like domain PF01576 Myosin tail
Function	Muscle contraction.

> Gene Ontology [ TOP ]
Biological Process	GO:0003012 muscle system process GO:0006936 muscle contraction GO:0009116 nucleoside metabolic process GO:0009119 ribonucleoside metabolic process GO:0009123 nucleoside monophosphate metabolic process GO:0009126 purine nucleoside monophosphate metabolic process GO:0009141 nucleoside triphosphate metabolic process GO:0009144 purine nucleoside triphosphate metabolic process GO:0009150 purine ribonucleotide metabolic process GO:0009161 ribonucleoside monophosphate metabolic process GO:0009167 purine ribonucleoside monophosphate metabolic process GO:0009199 ribonucleoside triphosphate metabolic process GO:0009205 purine ribonucleoside triphosphate metabolic process GO:0014823 response to activity GO:0030048 actin filament-based movement GO:0030049 muscle filament sliding GO:0033275 actin-myosin filament sliding GO:0042278 purine nucleoside metabolic process GO:0046034 ATP metabolic process GO:0046128 purine ribonucleoside metabolic process GO:0070252 actin-mediated cell contraction GO:1901657 glycosyl compound metabolic process
Molecular Function	GO:0000146 microfilament motor activity GO:0003725 double-stranded RNA binding GO:0003774 motor activity GO:0003779 actin binding GO:0005516 calmodulin binding GO:0016887 ATPase activity
Cellular Component	GO:0005859 muscle myosin complex GO:0015629 actin cytoskeleton GO:0016459 myosin complex GO:0016460 myosin II complex GO:0030016 myofibril GO:0030017 sarcomere GO:0032982 myosin filament GO:0043292 contractile fiber GO:0044449 contractile fiber part

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04530 Tight junction
Reactome	R-HSA-199991: Membrane Trafficking R-HSA-1445148: Translocation of GLUT4 to the plasma membrane R-HSA-5653656: Vesicle-mediated transport

Summary
Symbol	MYH4
Name	myosin, heavy chain 4, skeletal muscle
Aliases	MYH2B; MyHC-2B; MyHC-IIb; myosin, heavy polypeptide 4, skeletal muscle; myosin heavy chain 2b; myosin heavy ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MYH4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	MYH4
Name	myosin, heavy chain 4, skeletal muscle
Aliases	MYH2B; MyHC-2B; MyHC-IIb; myosin, heavy polypeptide 4, skeletal muscle; myosin heavy chain 2b; myosin heavy ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MYH4 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	MYH4
Name	myosin, heavy chain 4, skeletal muscle
Aliases	MYH2B; MyHC-2B; MyHC-IIb; myosin, heavy polypeptide 4, skeletal muscle; myosin heavy chain 2b; myosin heavy ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MYH4 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0	1
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0	1
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0	1
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-1.408	0.00813
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-1.15	0.505
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-1.739	0.388
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.587	0.475
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.914	0.527
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.006	0.997
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.144	0.747
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.144	0.828
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.09	0.599

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MYH4 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	12.3	-1.2	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	15.3	-4.2	0.745
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	28.6	17.6	11	0.476
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	16.7	-4.2	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	38.5	18.2	20.3	0.386
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	15.8	7.4	8.4	0.452
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	18.2	15.4	2.8	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	12.5	0	12.5	0.485
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	MYH4
Name	myosin, heavy chain 4, skeletal muscle
Aliases	MYH2B; MyHC-2B; MyHC-IIb; myosin, heavy polypeptide 4, skeletal muscle; myosin heavy chain 2b; myosin heavy ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MYH4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MYH4
Name	myosin, heavy chain 4, skeletal muscle
Aliases	MYH2B; MyHC-2B; MyHC-IIb; myosin, heavy polypeptide 4, skeletal muscle; myosin heavy chain 2b; myosin heavy ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MYH4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MYH4. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MYH4
Name	myosin, heavy chain 4, skeletal muscle
Aliases	MYH2B; MyHC-2B; MyHC-IIb; myosin, heavy polypeptide 4, skeletal muscle; myosin heavy chain 2b; myosin heavy ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MYH4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MYH4
Name	myosin, heavy chain 4, skeletal muscle
Aliases	MYH2B; MyHC-2B; MyHC-IIb; myosin, heavy polypeptide 4, skeletal muscle; myosin heavy chain 2b; myosin heavy ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MYH4 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MYH4
Name	myosin, heavy chain 4, skeletal muscle
Aliases	MYH2B; MyHC-2B; MyHC-IIb; myosin, heavy polypeptide 4, skeletal muscle; myosin heavy chain 2b; myosin heavy ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MYH4 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MYH4
Name	myosin, heavy chain 4, skeletal muscle
Aliases	MYH2B; MyHC-2B; MyHC-IIb; myosin, heavy polypeptide 4, skeletal muscle; myosin heavy chain 2b; myosin heavy ......
Chromosomal Location	17p13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MYH4 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse MYH4